PT  - JOURNAL ARTICLE
AU  - MARUYAMA, RYO
AU  - SAITO, SEIICHI
AU  - BILIM, VLADIMIR
AU  - HARA, NOBORU
AU  - ITOI, TOSHIYUKI
AU  - YAMANA, KAZUTOSHI
AU  - NISHIYAMA, TSUTOMU
AU  - ARAI, YOICHI
AU  - TAKAHASHI, KOTA
AU  - TOMITA, YOSHIHIKO
TI  - High Incidence of GalNAc Disialosyl Lactotetraosylceramide in Metastatic Renal Cell Carcinoma
DP  - 2007 Nov 01
TA  - Anticancer Research
PG  - 4345--4350
VI  - 27
IP  - 6C
4099  - http://ar.iiarjournals.org/content/27/6C/4345.short
4100  - http://ar.iiarjournals.org/content/27/6C/4345.full
SO  - Anticancer Res2007 Nov 01; 27
AB  - Background: In renal cell carcinoma (RCC), glycosphingolipids monosialosyl globopentaosylceramide (MSGb5) and GalNAc disialosyl lactotetraosylceramide (GalNAcDSLc4) were shown to be predictors of metastasis. Here we extended the research using a larger cohort of patients with a longer follow-up period, and reevaluate their relationship to malignant potential, metastasis and prognosis in patients with RCC. Patients and Methods: MSGb5 and GalNAcDSLc4 were examined in 114 primary RCCs by immunohistochemical method on cryostat sections. Results: GalNAcDSLc4 was detected in 13.2% of RCCs and was associated with a significantly higher incidence of metastasis at the time of primary visit (60.0% vs. 31.3%, p=0.0419) as well as de novo metastasis during follow-up (33.3% vs. 14.7%), and a shorter survival (p=0.0399). MSGb5 was detected in 51.8% of tumors and was not related to clinocopathological characteristics or survival. Conclusion: RCC patients with tumors positive for GalNAcDSLc4 are at higher risk of metastasis at the time of diagnosis and during follow-up. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved